

Novacyt Announces Bond Issue

Paris, France and Cambridge, UK – 6th April 2017 – Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces the Company has issued a convertible bond in the amount of €1,500,000 through the issuance of 1,500,000 bonds which are convertible into shares with a nominal value of €1.00 each ("OC17VATEL") in favour of FCPI Dividends Plus N° 4 fund and FCPI Dividends Plus N° 5 fund. On March 31, 2016, the Company recorded the subscription of these 1,500,000 OC17VATEL.

These OC17VATELs were issued in a single tranche with a maturity of 3 years and an annual interest rate of 7.9% and a non-conversion premium paid in arrears of 0.1%. This amount has been allocated to Novacyt SA. The OC17VATEL are convertible only in the event of non-compliance by the Company with its repayment obligations. Only then can the conversion be triggered by holder of the bonds. The conversion parity being 1.25 new shares of the Company for an OC17VATEL.

- End -

About Novacyt Group

The Novacyt Group is a leader in the field of cellular diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform NovaPrep® and molecular platform, genesig® Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

International

Brett Pollard / Victoria Foster Mitchell
FTI Consulting
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

France

Arnaud de Cheffontaines / Astrid Villette
FTI Consulting
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

NOVACYT

Graham Mullis
Chief Executive Officer
+44 (0)7901 514 121
graham.mullis@novacyt.com